topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2 Terminated
93 enrolled 27 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Phase 1/2 Terminated
67 enrolled
Phase l/II Study of Ruxolitinib for Acute Leukemia
Phase 1/2 Terminated
27 enrolled 6 charts
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Phase 1/2 Terminated
21 enrolled 33 charts
A Study of ONO-7475 in Patients With Acute Leukemias
Phase 1/2 Terminated
42 enrolled 47 charts
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
Phase 1/2 Terminated
6 enrolled 11 charts
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
1 enrolled 3 charts
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Phase 1/2 Terminated
187 enrolled 8 charts
GL-CLB-001
Phase 1/2 Terminated
13 enrolled
PIVOT IO 020
Phase 1/2 Terminated
15 enrolled 14 charts
MT-3724NHL001
Phase 1/2 Terminated
38 enrolled 20 charts
UF-AML-CE-101
Phase 1/2 Terminated
11 enrolled 15 charts
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
Phase 1/2 Terminated
7 enrolled 12 charts
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1/2 Terminated
70 enrolled 36 charts
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Phase 1/2 Terminated
19 enrolled 11 charts
PrE0901
Phase 1/2 Terminated
15 enrolled 5 charts
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase 1/2 Terminated
23 enrolled 13 charts
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase 1/2 Terminated
23 enrolled 12 charts
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
6 enrolled 6 charts
Cord Blood
Phase 1/2 Terminated
3 enrolled 8 charts
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Phase 1/2 Terminated
2 enrolled
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 1/2 Terminated
30 enrolled 17 charts
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
Phase 1/2 Terminated
9 enrolled 11 charts
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
Phase 1/2 Terminated
22 enrolled 9 charts
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Phase 1/2 Terminated
1 enrolled 8 charts
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Phase 1/2 Terminated
26 enrolled 12 charts
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Phase 1/2 Terminated
25 enrolled
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
Phase 1/2 Terminated
3 enrolled 6 charts
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Phase 1/2 Terminated
10 enrolled 13 charts
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
Phase 1/2 Terminated
4 enrolled 7 charts
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
12 enrolled 14 charts
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Phase 1/2 Terminated
1 enrolled 7 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Phase 1/2 Terminated
31 enrolled 24 charts
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
16 enrolled
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Phase 1/2 Terminated
6 enrolled
ALLPhi
Phase 1/2 Terminated
8 enrolled
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Phase 1/2 Terminated
5 enrolled
Bendamustine in Acute Leukemia and MDS
Phase 1/2 Terminated
27 enrolled 6 charts
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Phase 1/2 Terminated
25 enrolled